SIGNIFICANT DECREASE
CHOLESTEROL & TRIGLYCERIDE BLOOD LEVELS

Novel proprietary formulation of Cannabidiol (CBD) and Chitosan
that will benefit millions of patients suffering from dyslipidemia

CBD-OPPORTUNITY
THE OPPORTUNITY

CANNALEAN ADDRESSES AN UNMET NEED
Dyslipidemia is a condition in which one or more of the serum lipid (for example LDL cholesterol, triglycerides, etc.) levels are abnormal. Its prevalence is very common and as much as 50% of the adult population worldwide suffer from some kind of Dyslipidemia.
.…More Details →

CANNALEAN’s SOLUTION:
THE SOLUTION

Our pre-clinical in vivo results in Guinea pig and rat models show the effect of the novel formulation on cholesterol and triglycerides reduction, as compared to controls and each compound alone.
CANNALEAN Solution is a novel formulation of Cannabidiol (CBD), a non-psychotropic component of Cannabis, with chitosan,
…More Details →

CANNALEAN Biotech’s IP:

A provisional patent was filed on 2017 by Mor Research Applications, the Tech Transfer Company of Clalit Health Services and the PCT is now on the international phase.
The patent covers a composition comprising Cannabidiol (CBD) and chitosan for improving Dyslipidemia and other signs and symptoms of metabolic syndrome.